31.07.2018
Eckert & Ziegler Strahlen- und Medizintechnik AG DE0005659700
DGAP-News: Eckert & Ziegler Q2/2018: Increase in Revenue in all Business Segments
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s):
Half Year Results/Quarter Results
Eckert & Ziegler Q2/2018: Increase in Revenue in all Business Segments
31.07.2018 / 07:45
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Berlin, 31 July 2018. Berlin-based Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a specialist in isotope-related
applications in medicine, science and industry, generated an outstanding
result of EUR 1.62 per share in the first half year 2018. Compared with the
prior year, the Group's earnings per share increased by EUR 0.39 or 31 %.
The weak results from the first quarter of 2018 were thus more than
compensated for. The good results showed up in all segments. In the
industrial business (Isotope Products), sales in the energy sector in
particular increased, and with radiopharmaceuticals, the demand for isotopic
markers ensured record results. In the Radiation Therapy segment, sales of
afterloaders also exceeded the previous year's figures. Since the cyclotron
division has been sold in May 2017 and income and sales from discontinued
operations must be reported separately in accordance with IFRS 5, the
figures about the comparable period relate only to the continuing
operations.
Eckert & Ziegler attained record sales of EUR 81.0 million in the first half
of 2018. The sales increased by EUR 16.2 million, or 25 %, when compared to
the previous year. The Isotope Products segment - which increased its sales
by EUR 13.6 million or 33 % to EUR 54.2 million due to the sales of the
Gamma-Service Group acquired at the end of May 2017 and the increased demand
in the energy sector - experienced the largest growth spurt within the
continuing operations. Sales in the Radiation Therapy segment rose as well
by EUR 2.0 million or 16 % to EUR 14.2 million, driven by good sales of
afterloaders. The Radiopharma segment increased sales by 15 % to EUR 15.4
million. The reason for that is the increasing need for pharmaceutical
radioisotopes.
The strong euro had adverse effects on the sales growth in all segments due
to the adverse effects on sales made in foreign currency. Compared with the
previous year, the Group lost EUR 4.6 million that way, so the growth after
adjustment for currency effects would have totaled EUR 20.7 million or 32 %.
Organic, real sales growth - in other words, sales adjusted for currency
effects and excluding the acquisitions and disposals made in 2017 - amounted
to EUR 11.9 million or 18 %.
Since the 2018 half-year result contains only a few extraordinary effects
and the good business development included almost all of the main product
groups, the Executive Board now assumes that the consolidated earnings from
continuing operations will increase by at least 15 % for the fiscal year
2018 compared to the prior year. The previous target of EUR 2.20 therefore
increases to around EUR 2.50 per share. Sales are expected to be at around
EUR 160 million, assuming that the euro exchange rate does not exceed $
1.15.
The complete financial statements can be viewed here:
http://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz218e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN
DE0005659700), with around 800 employees, is one of the world's largest
providers of isotope-related components for radiation therapy and nuclear
medicine.
Contributing to saving lives.
Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, [email protected], www.ezag.de
---------------------------------------------------------------------------
31.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlenund Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
709197 31.07.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Eckert & Ziegler Strahlen- und Medizintechnik AG ISIN: DE0005659700 können Sie bei EQS abrufen
Medtech , 565970 , EUZ , XETR:EUZ